



Accelerating access to hepatitis C diagnostics and treatment

Overcoming barriers in low-
and middle-income countries

Global progress report 2020



Accelerating access to hepatitis C diagnostics and treatment

Overcoming barriers in low-
and middle-income countries

Global progress report 2020



Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020

ISBN 978-92-4-001900-3 (electronic version)

ISBN 978-92-4-001901-0 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Layout by 400 Communications.

Contents

Acknowledgements	iv
Abbreviations and acronyms	v
Executive summary	vii
I Introduction	1
II Overview of the global hepatitis C epidemic and response	5
III Progress in 12 selected countries	11
IV Key enablers for accelerating towards universal access to hepatitis C diagnostics and treatment	19
IV.1 Availability: Simplified norms and standards, more and improved product options	20
IV.2 Quality: Meeting quality assurance and product regulation standards	21
IV.3 Affordability: Lowering prices and patent-related barriers	25
IV.4 Equity: Addressing the needs of key and vulnerable populations	34
IV.5 Efficiency: Leveraging opportunities for procurement, financing and service delivery	36
V Future priorities	39
Annexes	42
Annex 1: Drug profiles	43
Annex 2: Summary of the DAA procurement situation in selected low- and middle-income countries with a high burden of hepatitis C, 2019	52
Annex 3: Low- and middle-income countries and areas not included in at least one voluntary licensing agreement, 2020	55
References	58

Acknowledgements

This publication was developed jointly by the Global HIV, Hepatitis and STIs Programmes (HHS) and the Division on Access to Medicines and Health Products (MHP) of the World Health Organization (WHO). The process was led by Françoise Renaud and Erika Dueñas Loayza, and coordinated by Daniel Low-Beer and Clive Ondari. The contributions of Fernando Pascual Martinez, who managed the data collection and conducted the interviews, Emmanuel Fajardo who conducted research on diagnostics, and Parijat Baijal, who was the lead writer, are gratefully acknowledged.

We particularly thank colleagues in ministries of health and in WHO regional and country offices for their contributions, as well as Fuqiang Cui, Boniface Dongmo Nguimfack, Philippa Easterbrook, Olufunmilayo Lesi, Niklas Luhmann, Gilles Forte, Kiu Siang Tay, Adriana Velazquez Berumen, Deusdedit Mubangizi, Maria Mercedes Perez Gonzalez, Irena Prat, Anita Sands, Dzintars Gotham and Nicole Homb from WHO headquarters. Bandana Malhotra edited the report.

We are grateful to Meg Doherty, Minghui Ren and Mariângela Simão for their overall support and leadership.

The following persons were interviewed for the report: François Bompert (Drugs for Neglected Diseases *initiative*, Switzerland), Esteban Burrone (Medicines Patent Pool, Switzerland), Jessica Burry (Médecins Sans Frontières, Switzerland), Jean Michel Caudron (United Nations Development Programme, Switzerland), Lorena Di Giano (Redla Red Latinoamericana por el Acceso a Medicamentos), Khalil Elouardighi (Coalition PLUS, Paris, France), Gamal Esmat (Cairo University, Egypt), Charles Gore (Medicines Patent Pool, Switzerland), Andrew Hill (University of Liverpool, United Kingdom), Priti Krishtel (I-Mak, United States of America), Vidhi Lohia (Clinton Health Access Initiative), Pauline Londeix (Observatoire pour la Transparence, France), Cécile Macé (United Nations Development Programme, Switzerland), Amina Maillard (Medicines Patent Pool), Mila Maistat (Medicines Patent Pool), Craig McClure (Clinton Health Access Initiative), Leena Menghaney (Médecins Sans Frontières, India), Othoman Mellouk (International Treatment Preparedness Coalition, Morocco), Sonjelle Shilton (Foundation for Innovative New Diagnostics), Ellen 't Hoen (Medicines Law & Policy, The Netherlands), Karin Timmermans (Unitaid, Switzerland), Pedro Villardi (Grupo de Trabalho sobre Propriedade Intelectual, Brazil), Marcela Vieira (Graduate Institute, Switzerland) and Ernst Wisse (Médecins du Monde, France). We are also grateful to colleagues in the Clinton Health Access Initiative, the Foundation for Innovative New Diagnostics, the Medicines Patent Pool and Unitaid for their comments during the finalization of the report.

Financial acknowledgments

Funding support for the development of the report was kindly provided by Unitaid. WHO also thanks the other institutions that provided staff time and made other contributions to the production of the report.

Abbreviations and acronyms

APH	Alliance for Public Health Ukraine	HIV	human immunodeficiency virus
API	active pharmaceutical ingredient	IVD	in vitro diagnostics
APRI	aspartate aminotransferase-to-platelet ratio index	LDV	ledipasvir
BMS	Bristol-Myers Squibb	MDM	Médecins du Monde
CHAI	Clinton Health Access Initiative	MSF	Médecins Sans Frontières
COVID-19	coronavirus disease 2019	MoH	Ministry of Health
DAA	direct-acting antiviral (medicine)	MPP	Medicines Patent Pool
DCV	daclatasvir	MSM	men who have sex with men
DND<i>i</i>	Drugs for Neglected Diseases <i>initiative</i>	NAT	nucleic acid testing
EASL	European Association for the Study of the Liver	PCR	polymerase chain reaction
EMA	European Medicines Agency	POC	point of care
EPO	European Patent Office	PWID	people who inject drugs
ERP	Expert Review Panel	RDT	rapid diagnostic test
FAS	Federal Antimonopoly Service (Russian Federation)	RNA	ribonucleic acid
FIND	Foundation for Innovative New Diagnostics	SDGs	Sustainable Development Goals
Global Fund	the Global Fund to Fight AIDS, Tuberculosis and Malaria	STI	sexually transmitted infection
GNI	gross national income	TB	tuberculosis
G/P	glecaprevir/pibrentasvir	TRIPS	Agreement on Trade-Related Aspects of Intellectual Property Rights
HBV	hepatitis B virus	UNDP	United Nations Development Programme
HCV	hepatitis C virus	USA	United States of America
		US FDA	United States Food and Drug Administration
		WHO	World Health Organization



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24127

